Prapela
Private Company
Funding information not available
Overview
Prapela has achieved a significant regulatory and clinical milestone with the FDA De Novo authorization of its Stochastic Vibrotactile Stimulation (SVS) bassinet pad for Neonatal Opioid Withdrawal Syndrome (NOWS) in April 2025, creating a unique, device-based therapeutic class. The company's technology is clinically proven to provide a consoling effect equivalent to caregiver holding, adjunctive to the standard Eat, Sleep, Console (ESC) care protocol, aiming to reduce hospital stays and caregiver burden. With a clear mechanism targeting brainstem autonomic stability and a hospital-ready design, Prapela is positioned to address a growing public health crisis with a non-pharmacological solution, while also developing an incubator pad for preterm apnea. The company operates as a private, commercial-stage entity shipping its authorized device to US healthcare facilities.
Technology Platform
Stochastic Vibrotactile Stimulation (SVS): A platform delivering low-amplitude, random-interval vibrations to engage the somatosensory system and provide sub-arousal input to brainstem autonomic networks, stabilizing breathing rhythm and cardiorespiratory function.
Opportunities
Risk Factors
Competitive Landscape
Prapela's SVS device is in a unique regulatory class as the only FDA-authorized device for NOWS. It directly contrasts with responsive rocking bassinets, which are not authorized for NOWS and a recent study indicated worsened outcomes. For preterm apnea, potential future competitors include other non-invasive respiratory support devices, but Prapela's neuromodulation approach appears distinct.